Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024

Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024

DelveInsight’s, “Systemic Inflammatory Response Syndrome (SIRS) – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Systemic Inflammatory Response Syndrome (SIRS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Systemic Inflammatory Response Syndrome (SIRS) Understanding

Systemic Inflammatory Response Syndrome (SIRS): Overview

Systemic inflammatory response syndrome (SIRS) is a heightened defense response of the body to various stressful conditions to the body. It is nonspecific and can be caused by inflammation, ischemia, infection, trauma, sepsis, or other stresses combined.

Symptoms

Clinically, symptoms of SIRS can be identified by two or more symptoms which would include hypothermia or fever, tachypnoea, tachycardia, and change in blood leucocyte count.

Diagnosis

Diagnosing Systemic Inflammatory Response Syndrome (SIRS) may be done by assessing a range of tests that may include complete blood cell count, blood cultures, sputum gram stain and culture, urinalysis and culture, liver profiles, cardiac enzymes, venous or arterial blood gases, lactate, and other tests. Even though no imaging studies exist for SIRS, they may be prescribed based on etiology of the condition.

Treatment

Presently, there is no cure available for the treatment of Systemic Inflammatory Response Syndrome (SIRS). The treatment is majorly supportive and symptomatic. The management of symptoms is done by treating the underlying etiology.

Systemic Inflammatory Response Syndrome (SIRS) Emerging Drugs Chapters

This segment of the Systemic Inflammatory Response Syndrome (SIRS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I/II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Systemic Inflammatory Response Syndrome (SIRS) Emerging Drugs

• Exebacase: ContraFect

Exebacase is a recombinant cell wall hydrolase enzyme with strong bactericidal activity against Staph auerues, which is a major causative agent of bloodstream infections, commonly known as bacteremia. It targets the peptidoglycan wall of the Staph aureus bacteria. Some in vitro and vivo studies have also reported Exbebacase highly effective against biofilms.

• Rezafungin acetate: Cidera Therapeutics

Rezafungin acetate is a novel molecule from the echinocandin class of antifungals. It is being developed by Cidera Therapeutics for the prevention and treatment of serious, and invasive fungal infections. It is being developed as once-weekly and high exposure therapy for the treatment of invasive candidiasis and candidemia. It is a new beta-glucan synthase inhibitor which disturbs fungal cell glucan synthesis.

Further product details are provided in the report……..

Systemic Inflammatory Response Syndrome (SIRS): Therapeutic Assessment

This segment of the report provides insights about the different Systemic Inflammatory Response Syndrome (SIRS) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Systemic Inflammatory Response Syndrome (SIRS)

There are approx. 10+ key companies which are developing the therapies for Systemic Inflammatory Response Syndrome (SIRS). The companies which have their Systemic Inflammatory Response Syndrome (SIRS) drug candidates in the early to advanced stage, i.e. phase I and Phase III include Cidera Therapeutics and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and Phase II/III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Systemic Inflammatory Response Syndrome (SIRS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Systemic Inflammatory Response Syndrome (SIRS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II/II, II, I/II, I, preclinical and discovery stage. It also analyses Systemic Inflammatory Response Syndrome (SIRS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Systemic Inflammatory Response Syndrome (SIRS) drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Inflammatory Response Syndrome (SIRS) R&D. The therapies under development are focused on novel approaches to treat/improve Systemic Inflammatory Response Syndrome (SIRS).

Systemic Inflammatory Response Syndrome (SIRS) Report Insights

• Systemic Inflammatory Response Syndrome (SIRS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Systemic Inflammatory Response Syndrome (SIRS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Systemic Inflammatory Response Syndrome (SIRS) drugs?
• How many Systemic Inflammatory Response Syndrome (SIRS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Inflammatory Response Syndrome (SIRS)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Systemic Inflammatory Response Syndrome (SIRS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Systemic Inflammatory Response Syndrome (SIRS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cidera Therapeutics
• ContraFect
• Scynexis

Key Products

• Rezafungin acetate
• Exebacase
• Ibrexafungerp citrate